Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Horizon Pharma licenses MEDI-4945 from MedImmune

Jan. 11, 2018

Retrophin and Censa Pharmaceuticals to collaborate on CNSA-001 for PKU

Jan. 11, 2018

Akcea Therapeutics starts phase IIb study of AKCEA-APOCIII-LRx

Jan. 10, 2018

Teijin returns somavaratan rights to Versartis

Jan. 10, 2018

FDA accepts Ionis' inotersen NDA for priority review

Jan. 9, 2018

Ultragenyx reports first cohort data from phase I/II study of DTX-301 to treat OTC deficiency

Jan. 9, 2018

Final draft guidance by U.K.'s NICE recommends use of Strimvelis for ADA-SCID

Jan. 8, 2018

Cadent Therapeutics discovers new potassium channel modulators

Jan. 8, 2018

EMA accepts Evenity MAA in osteoporosis

Jan. 8, 2018

EMA gives orphan drug designation to Spruce Biosciences' SPR-001

Jan. 8, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...